Qilibri has been acquired by SP2L (NaturAvignon Laboratory)
September 2023 — The owners of Qilibri, which include the co-founders, Day One Entrepreneurs & Partners, Pléiade Venture and Financière Saint-James, and business angels, have sold the company to SP2L (NaturAvignon Laboratory).
Qilibri is a French digital-native brand founded in 2019 by two experienced entrepreneurs, offering a holistic approach to weight loss through healthy pre-cooked meals delivery, professional dietary assistance and sports training. Qilibri uses algorithms to determine customers’ needs in order to maximize weight loss and lasting results, compared with standard offers. Qilibri’s objective is to redesign weight loss with a 360° offer based on a 100% customized program, which includes a qualitative nutrition offer designed by expert dieticians and a complete service offer via weekly professional dietary coaching, access to an online community and sport training, in partnership with a leading fitness club operator. Qilibri’s innovative, fully customized and efficient offer has enabled the company to quickly develop a community of approximately 200,000 people. Today, Qilibri is a brand recognized for its ability to leverage customers’ data, enabling to build a personalized and qualitative relationship throughout the program.
Founded in 2003, Groupe SP2L (Laboratoire NaturAvignon) offers safe, effective dietary supplements, health products and professional support to help seniors improve their health. Groupe SP2L comprises two brands: Laboratoire NaturAvignon, an emblematic brand in nutraceuticals for 20 years, and Blanche Bresson Institut, a digital brand of natural and organic food supplements.
Our role in the transaction
Oaklins’ team in France acted as sell-side M&A advisor in the transaction.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn more